Introduction Photodynamic therapy, a minimally invasive oncological modality, has been in use for over 20 years. However, little clinical data is available on its non-oncological efficacy. Several laboratory-based trials on animals have suggested that this technology may be applicable as an antimicrobial therapy. In orthopaedics, where implants and metal work are placed in deep tissue planes, a potential risk of infection is treated very seriously. Infection not only increases patient morbidity and mortality but also the burden on healthcare system. Proposing a new modality that can instantly tackle this problem. This critical review discusses surgical site infections subjected to photodynamic therapy. Conclusion Surgical care should be state of the art with careful attention to strategies that avoid the development of SSIs. When SSI does occur, superficial and deep wound infections can be treated using PDT by applying topical photosensitiser to the area followed by light illumination.
Introduction

Surgical site infection (SSI)
Nearly all surgical wounds are contaminated by microbes; however, in-nate immunity neutralises this effect. In few cases, infection may develop. SSIs account for 10% of all nosocomial infections. Although there is no international criterion for diagnosis, authorities seem to agree that an infection of the tissues around or within the surgical wound within the first 4 weeks of surgery represents 'surgical site infection'. SSI significantly increases patient morbidity as well as mortality [1] [2] [3] [4] [5] [6] . Incisional SSIs can be either superficial (i.e. skin and subcutaneous tissue) or deep (i.e. fascial and muscle layers) or they can be organ/space SSIs; the latter may involve anatomical structures that are either unopened or manipulated during the surgery [1] [2] [3] [4] [5] [6] . Several factors have been attributed to cause this surgical setback, including microbial-and host-related factors as well as surgical factors. Host-related factors involve age, medical background, immunodeficiency, malnutrition, poor tissue perfusion and poor wound characteristics (such as poor skin, non-viable tissue, foreign body and haematoma). On the other hand, surgical factors include lengthy operation, intraoperative contamination and poor surgical technique. Prolonged hospital stay, immobility and hypothermia are responsible for majority of nosocomial infections, including SSIs [1] [2] [3] [4] [5] [6] . Simple SSIs usually present as a discharging skin wound, and sometimes, a sinus can be identified tracking to the skin surface from a deeper source. Involvement of deeper structures may lead to abscess formation, thereby complicating management (i.e. pelvic and spinal infections) [1] [2] [3] [4] [5] [6] . Management is conventionally via antimicrobials and/or surgical approach. Surgical wound abscess is usually managed by incision, debridement and drainage. Deeper wounds are left open to allow healing from the inside out (i.e. healing by secondary inten-tion). Sometimes, long-term antimicrobials are required, especially when dealing with infections spreading tothe underlying structures (i.e. muscle and bone) [1] [2] [3] [4] [5] [6] . In orthopaedic surgery, SSIs are uncommon; however, they can be devastating when theydo occur. Optimizing the patient's general medical condition pre-operatively and eliminating or diminishing the modifiable risk factors for infection has been shown to lower the risk of SSIs [1] [2] [3] [4] [5] [6] .
Prophylactic antimicrobials and resistance
In the 1960s, experimental data demonstrated the value of prophylactic antimicrobials. According to early studies at that time, high dose level of antibiotics in blood circulation has to be achieved at the time of first incision in order to preventan infection. Prophylaxis is generally required for clean-contaminated and contaminated wounds. Most authorities recommend intravenous administration of prophylactic antimicrobials 30 min prior to the first incision [7] [8] [9] [10] [11] [12] [13] . The use of prophylactic antimicrobials in orthopaedic surgery prior to the first incision has shown to be effective in reducing SSIs, especially in open reduction and internal fixation in trauma surgery, spinal surgery as well as hip and knee surgeries [7] [8] [9] [10] [11] [12] [13] . Staphylococcus aureus is most commonly identified in infected surgical wounds. Other bacteria such ascoagulase-negative staphylococci [including methicillin resistant Staph-ylococcus aureus (MRSA), which is proving to be a menace to modern day surgery], Escherichia coli, Pseudomonas aeruginosa and Enterobacter species have also been identified [7] [8] [9] [10] [11] [12] [13] . There has been an increase in the prevalence of antibiotic-resistant bacterial infections in clinical settings. This is mainly attributable to an increase in the prescription volume of anti-microbials, which in turn is attributable to various factors (Table 1) . Antibioticresistance usually results from horizontal gene transfer as well as unlinked point mutations; four mechanisms have been identified: (1) drug inactivation or modification (i.e. some penicillin-resistant bacteria), (2) alteration of metabolic pathways (i.e. sulphonamide-resistant bacteria), (3) alteration of target sites (i.e. MRSA and other penicillin-resistant bacteria), and (4) reduced drug accumulation. The most common of these pathogens are highlighted in Table 2 7-13 . It is only time before the emergence of new microbial strains that will be resistant to all known antimicrobial agents. The ability to manage deep surgical wounds via antibiotics may soon come to an end. The only remaining alternative may be surgery that could lead to tissue or limb loss, the latter being a significant loss to a patient. Despite attempts to modify and create new antimicrobials which may help tackle this problem, the problem may spersist as new mutant strains will eventually develop resistance to newly developed antimicrobial agents. This possibility was evident during the testing phases of many new anti-microbial agents [7] [8] [9] [10] [11] [12] [13] 15, 16 .
The theory of photodynamic inactivation (PDI) necessitates cell exposure to specific wavelength light energy that leads to exogenous or endogenous excitation of photosensitiser molecules, resulting in the production of reactive oxygen species (ROS). ROS causes cell inactivation and death through modification of intracellular components. Advances in understanding of microbial pathophysiology have led to identification of a series of pathways and phenotypes that serve as potentialtargets for antimicrobial drug discovery. Investigations of these phenotypic elements in concert with PDT have been reported, which mainly focus on multidrug efflux systems, biofilms, virulence and pathogenesis determinants. In many instances, the results are encouraging; however, they are still at preliminary phases and would require further investigations 15, 16 . PDT has been suggested as a new technique to inactivate microorganisms as it does not lead to the selection of mutant resistant strains; a clear benefit in contrast to standard antibiotic therapy. This idea was initially presented by Rabb (1900), who described the antimicrobial effect of acridine and light on Paramecium species. Soukos et al. 17 studied the laser-induced effects of toluidine blue O on normal human gingival keratinocytes and fibroblasts in vitro. The preliminary results of this study showed aneradication of Streptococcus sanguis, suggesting that a system for lethal photosensitisation of bacteria causing periodontal diseases could be developed. This demonstrated the microbial selectivity of PDT. PDI has been studied in bacteria, where PDI of Escherichia coli was primarily dependent on genomic DNA photo damage 18 , while in other studies, cellular envelope appears to be the main component being assaulted by PDT 19, 20 . In a study by Bertoloni et al., two S. aureus strains were subjected to PDT, and the electrophoretic analysis of cytoplasmic membrane proteins and DNA suggested that the membrane represented the primary target of the photo process, while the DNA may be a secondary target 21 .
Several studies have reported on the anti-staphylococcal activity of PDT. In vitro studies using various photosensitisers have shown a complete bactericidal effect on various bacteria, including MRSA [22] [23] [24] [25] [26] [27] [28] [29] [30] . Other Gram-positive bacteria have been investigated to a lesser extent; however, they, including Propionibacterium acnes 31, 32 and Listeria monocytogenes 33 , have been reported to respond equally well to PDT.
The in vitro bactericidal effect of PDT on Gram-negative bacteria was also investigated and it was found to have a high bactericidal effect on Haemophilus parainfluenzae 34 , Prevotella and Porphyromonas species [35] [36] [37] , Helicobacter mustelae 38 , E. coli B, Acinetobacter baumannii, and P. aeruginosa 39, 40 . PDT of Gram-positive and Gram-negative bacteria in animal models hasproven to be as successful as in in vitro studies in inactivating the causative bacteria [41] [42] [43] [44] [45] [46] . As yet, clinical PDT for infections has been mainly in the field of dermatology using 5-aminolevulanic acid (5-ALA) and in dentistry using phenothiazinium dyes-a study concluded after peer-reviewing the published literature between 1960 and 2011. The authors expected to observe the applications of PDT to more challenging infections using advanced antimicrobial photosensitisers targeted to microbial cells in the years to come 16 . Except for E. coli, there was a significant decrease in the survival of Staphylococcus intermedius, Streptococcus canis and P. aeruginosa following ALA-PDT. A single treatment required 2-3 h of light exposure. The data from this particular study suggested that PDT may be a possible treatment option for wound infections, but repeated treatments or alterations in the photosensitiser or its carrier may be required to decrease treatment times 41 . The aim of this critical review is to discuss surgical site infections in orthopaedic surgery.
Discussion
Application of PDT to surgical wounds
The literature reports significant advances in the application of PDT as an antimicrobial modality that targets those pathological microorganisms which cause wound infections. If this antimicrobial modality is applied properly using an appropriate photosensitiser and matching light properties, a high bactericidal rate can be achieved. However, the efficacy and safety of PDT on surgical wounds requires confirmation by appropriately designed human clinical trials. With all this overwhelming evidence, there is no doubt that we are entering an age of human clinical trials when it comes to the inactivation of microorganisms using PDT 16, 41 . The issue of photosensitiser selectivity has been raised at a very early stage prior to clinical trials. Hamblin and Dai 47 highlighted a crucial point with regard to selectivity-a photosensitiser that binds to microbial cells versus the one that binds to all other components in a complex milieu. According to these authors, theoretically, 100 times more PDT is required to achieve the same high bactericidal effect that was achieved in in vitro and in vivo animal models. This was explained by an increase in the likelihood that the photosensitiser may bind to other components in a complex milieu, thereby reducing its availability for stronger PDT effect.
Furthermore, the photosensitiser and light penetration may be affected by thick pus and dead tissue. It is expected that each wound should be opened and pus drained and that debridement and washout should be performed prior to the application of PDT in order to maximise the penetration of the photosensitiser and light. This would theoretically increase the efficacy of PDT. Challenges • Education to surgeons: an editorial highlighted the fact that surgeons do not possess the adequate knowledge when it comes to PDT and its potential applications 47, 48 .
• Translation from laboratory science to human clinical trials: several factors need to be assessed and reviewed. These include elimination of pathogens, selectivity, inflammatory and immune processes of human tissues, collateral damage and systemic effect 47, 48 .
• PDT effect on the local vessels may causeischaemia; this may potentially affect wound healing, leading to re-infection 47 .
• Vascular and cellular mechanisms of the treated infective inflammation may allow the involved tissue to defend and protect itself 48 .
• Long term effect of PDT exposure on human tissues.
• Continued local and systemic influence of PDT once actual therapy has ceased.
Proposing a trial
A human clinical trial is a step in the right direction.
We propose an open, phase I, dose-escalating and deescalating study to evaluate the safety and efficacy of porphyrin-or ALAbased photosensitiser-based PDT in patients suffering from deep SSIs following trauma and orthopaedic operations. The primary objective of this study will be to assess the safety and efficacy of the porphyrin-or ALA-based photosensitiser and determine the maximal tolerated dose;
Primary objecti ve
To assess the safety and effi cacy of the porphyrin-or ALA-based photosensiti ser and determine the maximal tolerated dose Secondary objecti ve To evaluate toxicity, including skin photosensiti vity
To determine the pharmacokineti cs of the drug in humans
To document the anti bacterial acti vity Eligible pati ents Eligible pati ents will be included in 5 cohorts. The initi al interventi on will involve incision and drainage of the abscess, followed by the applicati on of the photosensiti ser. The initi al starti ng dose will be 2 mg/kg. The drug will be administered as a topical soluti on to washout the infected wound.
The illuminati on will follow aft er 60 min. The illuminati on will be with red light (laser 630 nm), fl uence of 100-200 J/cm 2 and fl uence rate of 10 mW/cm 2 . No anti bacterial cover will be administered aft er the interventi on.
Comparati ve arm
Eligible pati ents will have incision, debridement and drainage of the deep surgical site abscess with anti bacterial cover as indicated in the local hospital microbiology guidelines.
Dose escalati on
Will proceed according to a modifi cati on of Simon's accelerated ti trati on design. The number of pati ents recruited will depend on the dose limiti ng toxicity (DLT) experienced. A total of 10 pati ents will be included at each dose level if no more than 1 pati ent experiences DLT.
Dose de-escalati on Additi onal cohorts may be added pending the outcome of the previous cohorts and discussions between the investi gators.
Disconti nuati on from the study
The disconti nuati on of a pati ent from the study will occur in an event of infecti on progression or DLT.
Target populati on Pati ents with SSIs requiring incision, debridement and drainage post-trauma and orthopaedic operati ons. SSIs to be subjected to PDT and verifi ed by microbiological investi gati ons include infecti ons caused by Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, non-life threatening Streptococcus pyogenes and Pseudomonas aeruginosa.
Safety
An assessment of all adverse events experienced since treatment visit and assignment of CTCAE grades to all those considered to be drug related will be done at all visits. Adverse events will be followed unti l resolved. Blood sampling will be performed to check standard haematological and biochemical parameters and vital signs. Fluorescence and skin photosensiti vity will be measured and followed unti l values return to normal.
Study durati on
Pati ent enrolment is esti mated to take 4 weeks. The study is expected to last for 19 months.
debridement and drainage posttrauma and orthopaedic operations. SSIs to be subjected to PDT and verified by microbiological investigations will include infections caused by S. aureus, MRSA, non-life threatening Streptococcus pyogenes and P. aeruginosa.
Patients will be enrolled for a period of 4 weeks and performance status will be recorded pre-and post-intervention. Each patient in the in-tervention and control groups will undergo incision and drainage. Topical photosensitiser will be administered the secondary objective will be to evaluate the toxicity, including skin photosensitivity, in order to determine the pharmacokinetics of the drug in humans and to document the antibacte-rial activity (Table 3) . 
Day 28
Pati ent demographics at the site of the infected surgical wounds in the intervention groups, and illumination will follow within 30 min. Pain scoring, vital signs, blood screening, blood and urine PK and microbiological assessment will be performed on a regular basis. Assessment of the outcome will be documented through clinical photography, fluorescence and skin sensitivity testing, bioluminescence, wound check and assessment of the bactericidal effect. Adverse events will be documented and subsequently reported (Table 4) .
Conclusion
In an ideal world, surgical care should be state of the art with careful attention to strategies that avoid the development of SSIs. As mentioned previously, optimisation of patient medical status (Table 5) , appropriate aseptic techniques and surgical site preparation should help in preventing complications. Intraoperatively, application of good basic surgical skills, accurate tissue dissection, suitable selection of suture materials and appropriate wound closure is paramount.
However, when SSI does occur, the wound should be immediately opened, pus evacuated and debridement and washout of the dead tissue and debris should be performed.
During this time, antimicrobial
When resistance develops, a surgeon usually seeks input from a local microbiology department, which may suggest another medical therapy as guided by microscopy, culture and sensitivity of the infected inflammatory sample acquired from the surgical wound. The new therapy is most likely to cover a wide spectrum of pathogens, increasing the chance of developing multidrugresistant strains. If the wound continues to deteriorate, further surgical debridement may be indicated.
Superficial and deep wound infections can be treated using PDT by applying topical photosensitiser to the area followed by light illumination. For example, in burn infections which carry high mortality, Gram-positive bacteria, especially S. aureus, colonize these wounds at an early stage and are known to develop multidrug-resistance. These can be inactivated by PDT in in vitro and in vivo animal models. cover is a requirement which will be guided by clinical wound healing and inflammatory markers.
